All News Oncopeptides AB

Equities

ONCO

SE0009414576

Market Closed - Nasdaq Stockholm Other stock markets 11:29:41 2024-05-23 am EDT			5-day change	1st Jan Change
2.695 ^SEK	-0.92%		-6.91%	-64.82%

May. 16	Oncopeptides AB Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress	CI
Apr. 15	Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Invitation to presentation of the Q1 report 2024	May. 21	AQ
Oncopeptides presents new data highlighting treatment benefits of Pepaxti in high-risk multiple myeloma patients at the COMy Congress	May. 16	AQ
Oncopeptides AB Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress	May. 16	CI
Oncopeptides publishes final outcome in the fully guaranteed rights issue	May. 06	AQ
Annual General Meeting in Oncopeptides AB (publ)	Apr. 29	AQ
Oncopeptides publishes the 2023 Annual Report	Apr. 22	AQ
Oncopeptides publishes prospectus relating to the rights issue	Apr. 17	AQ
Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)	Apr. 15	AQ
Oncopeptides secures national reimbursement for Pepaxti in Spain	Apr. 15	AQ
Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	Apr. 15	CI
Oncopeptides announces final terms for the fully guaranteed rights issue	Apr. 08	AQ
Oncopeptides releases first quarter 2024 sales	Apr. 04	AQ
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	Apr. 04	CI
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	CI
Extraordinary General Meeting in Oncopeptides AB (publ)	Mar. 13	AQ
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization	Mar. 13	MT
Oncopeptides : Oncopeptalks on the company's rights issue	Mar. 13	PU
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026	Mar. 13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Oncopeptides AB

Equities

ONCO

SE0009414576

All News

Filters